Search Results
Search results for "neuroma model"
Results found for "neuroma model"
- Robert J. Lefkowitz: Beta-Adrenergic Receptors, the GPCR Family, and Fifty Years of Discovery | Dr. GPCR Ecosystem
His research established the beta-2 adrenergic receptor as the primary model system for understanding Beta-adrenergic receptors as a model system — Why the adrenergic system, with its rich pharmacological
- From Curiosity to Breakthrough: Ajay Yekkirala on GPCR Innovation | Dr. GPCR Ecosystem
interested in translational innovation Biotech investors and strategic leaders seeking new drug development models
- Fluorescent Probes for GLP-1R and GIPR Imaging: From Cell Assays to In Vivo Systems | Dr. GPCR Ecosystem
masterclasses with leading researchers Structured networking for scientists and biotech professionals Nonprofit model
- GPCR Masterclass Live Courses | Dr. GPCR Ecosystem
Pierce | Midewestern University Introduction to GLP-1 pharmacology Translational Pharmacology & Disease Models You're engaging directly with the expert — not submitting a question to a moderator.
- Dr. Roger Sunahara | Dr. GPCR Ecosystem
The structure was first snapshot of the agonist- and G protein-bound GPCR, providing valuable models We have identified several GPCR ligands that allosterically modulate orthosteric ligand binding and target
- Receptor Signaling Bias: A Valuable and Accessible Property of New Drug Candidates | Dr. GPCR Ecosystem
masterclasses with leading researchers Structured networking for scientists and biotech professionals Nonprofit model
- Dr. GPCR Team | Dr. GPCR Ecosystem
elucidating the molecular basis of membrane protein signalling using quantitative assays and molecular modelling Further down the track, he aims to apply this knowledge to develop novel chemical treatments for neuronal
- Scaling GLP 1 Receptor Tools Through Academia Industry Collaboration | Dr. GPCR Ecosystem
validation in GPCR assay design Building reagents that must work in complex tissues, not just simplified models Her work centers on GPCR modulators, synthetic chemistry, and enabling robust biological assays through
- GPCR Masterclass: Advanced Pharmacology & Drug Discovery | Dr. GPCR
Jacobson, Matteo Pavan Structure-Based Design of Modulators of Purinergic GPCRs <p class="font_8">Watch Programs <p class="font_8">Watch Now</p> Terry Hebert GPCR Signaling in iPSC-Derived Cardiac Disease Models Revolution in GPCR Biology <p class="font_8">Watch Now</p> Bryan Roth GPCR Molecular Glues: Biased Modulation
- Tuning GPCR System Sensitivity: Revealing True Drug Activity Through Functional Volume Control | Dr. GPCR Ecosystem
The same approach distinguishes what an allosteric modulator does to affinity versus efficacy, including masterclasses with leading researchers Structured networking for scientists and biotech professionals Nonprofit model
- Silvio Gutkind: Building a Lab That Doesn't Shut Down | Dr. GPCR Ecosystem
Gutkind a pre-built mental model for what to freeze, what to protect, and what to let continue.
- GPCR Webinars | Dr. GPCR Ecosystem
constitutive activity, inverse agonism How volume control reveals essential properties of allosteric modulators Each session explores mechanistic models, translational challenges, and real-world therapeutic implications GPCR pharmacology, signaling, structural biology, allosteric modulation, biased agonism, assay design
- GPCR University | Dr. GPCR Ecosystem
Pierce | Midewestern University Introduction to GLP-1 pharmacology Translational Pharmacology & Disease Models
- Yamina's Corner | Dr. GPCR Ecosystem
Organizations Elevate Scientific Offerings: Refine and optimize your GPCR assay platforms and in vitro models
- Foord: Serendipity, RAMPs, And Industrial GPCR Pharmacology | Dr. GPCR Ecosystem
several GPCRs including GABA B and carboxylic acid receptors, and discovery of a prostaglandin EP4 modulator it combined high receptor density with practical availability, illustrating how pragmatic choices in model
- Brian Arey - Part 2: GPCR Drug Discovery and the Science Nobody Publishes | Dr. GPCR Ecosystem
and metabolic disease biology, with contributions to multiple clinical programs including preclinical models
- Debbie Hay: Class B GPCRs, RAMPs, and the Migraine Pharmacology Gap | Dr. GPCR Ecosystem
heterodimers and the limits of current characterization tools Structural biology of RAMPs - allosteric modulation structurally obvious, making ligand selectivity considerably harder to engineer than a direct-contact model fluorescence complementation in vivo 26:42 Structural data and what it reveals about how RAMPs actually modulate
- Ross Cheloha: Nanobody-GPCR Conjugates and the Engineering of Receptor Selectivity | Dr. GPCR Ecosystem
In this conversation, he describes how attaching a moderately active peptide to a receptor-targeted nanobody The working model is that the nanobody anchors the conjugate at the receptor surface, positioning the
- Dr. John Streicher: Reorganizing Opioid Signaling Beyond the Receptor | Dr. GPCR Ecosystem
Listeners will get a concrete look at what it means to modulate opioid pharmacology downstream of the pharmacology as an underexplored route to safer opioid therapy Intermittent fasting as a metabolic modulator six-hour feeding window for seven days increased morphine's antinociceptive efficacy in multiple pain models Brian Blagg's KU-32 actually promotes neuronal survival in diabetic peripheral neuropathy and is now downstream of the opioid receptors work, including the unique organization of chaperone protein Hsp90 modulation
- Masha Niv: Bitter Taste Receptors and the Drug Discovery Blind Spot | Dr. GPCR Ecosystem
Her lab uses homology modeling, machine learning, and collaborative sensory experiments to predict bitterness
- Revvity | Dr. GPCR Ecosystem
All four formats are validated in well-established models like GLP1R and Mu opioid receptor (MOR), and
- Antony Boucard: Adhesion GPCRs and the Molecular Code of Synapse Formation | Dr. GPCR Ecosystem
formation — how adhesion GPCRs, working alongside classical cell adhesion molecules, determine which neuronal 25 years of no regrets 22:10 Université de Sherbrooke's industry-integrated curriculum and what it modeled proteins expressed as various alternatively spliced isoforms thus potentially resulting in differential modulation
- Exploring Career Paths in GPCR Research with Dr. Jacek Mokrosiński | Dr. GPCR Ecosystem
Yamina will schedule a future talk with Jacek about GPCRs as therapeutic modalities. The discussion revealed their interest in GPCRs as therapeutic modalities and possible future collaborations
- Joseph Kim: Structural Biology and Drug Discovery at GPCRs | Dr. GPCR Ecosystem
and κ-opioid receptors, and how structural insights can guide the development of new pharmacological modulators New Tools Enable Re-exploring Old Questions Advances in cryo-EM, computational modeling, and machine That unusual binding mode might explain why it has been so difficult to identify small-molecule ligands Yamina Berchiche: Unless you start thinking about allosteric modulators. Dr. Joseph Kim: Right—and once you start thinking about allosteric modulation, you open an entirely new set
- The Practical Assessment of Signaling Bias | Dr. GPCR Ecosystem
📌 Measuring Bias: A Quantitative Approach 🔹 The operational model provides a structured way to measure
- Anita Nivedha: Computational Dynamics of Ligand Bias in GPCR Signaling | Dr. GPCR Ecosystem
These residues may represent potential targets for allosteric modulators that reshape receptor signaling And now that I work with peptide drug modalities, I’m interested in peptide-binding GPCRs.
- Fresh, Fresh, GPCR News ❇ Feb 17 - 23, 2025 | Dr. GPCR Ecosystem
April 1 - 3, 2025 | 2nd Peptide-Based Therapeutics Summit - USA April 2 - 3, 2025 | New therapeutic modalities larval growth and embryonic development in the multivoltine strain of Bombyx more Profiling Allosteric Modulators β-arrestin-1/endothelin axis in human ovarian fibroblasts Methods & Updates in GPCR Research Histamine-modulated



















